Create Jira Ticket
Something went wrong.
This idea cannot be sent to Jira.
This idea cannot be sent to Jira.
Gathering votes
Thanks for your vote
This voting milestone has now ended, and the idea has progressed to a private milestone
Thanks for approving the idea
This milestone has now ended, and the idea has progressed to a private milestone
Reviewing methods of drug delivery i.e. changing IV therpay to s/c where option available e.g. tocilizumab and potentially belimumab
Decreasing footfall in the rheumatology day case unit so that we can ensure social distancing when our immunocompromised patients attend for treatment.
What is needed to sustain the change?
Ongoing access to these s/c drugs
What is your region?
North East
edited on Jul 13, 2020 by
Kyle Beacham
I've heard positive comments from patients about this too - not having to come in for treatment is a benefit not just related to covid. Only negatives I have heard is where people are expected to self administer without having access to training on how to do it because no nurse was available to do the training.
Reply 0
Status labels added: Choice, Community Care, Education, Medication, Patient Activation, Patient Selection, Staff & Patient Collaboration, Supported Self-Management, Horizon 1
Reply 0
The idea has been progressed to the next milestone.
Reply 0
Status labels removed: Choice, Community Care, Education, Medication, Patient Activation, Patient Selection, Staff & Patient Collaboration, Supported Self-Management
Reply 0